Lily Cheung Net Worth

What's Lily Cheung's mailing address?

Lily's mailing address filed with the SEC is C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Pliant Therapeutics

Over the last 4 years, insiders at Pliant Therapeutics have traded over $16,925,448 worth of Pliant Therapeutics stock. The most active insiders traders include Group, Llc Green Jeremy Red..., Rock Ventures Iii, L.P.Thir... oraz Thomas A Mccourt. On average, Pliant Therapeutics executives and independent directors trade stock every 24 days with the average trade being worth of $221,612. The most recent stock trade was executed by Eric Lefebvre on 10 July 2024, trading 12,319 units of PLRX stock currently worth $142,408.

What does Pliant Therapeutics do?

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Pliant Therapeutics executives and stock owners

Pliant Therapeutics executives and other stock owners filed with the SEC include:

• Dr. Bernard Coulie M.B.A., M.D., MBA, Ph.D.,
  Pres, CEO & Director
• Dr. Éric Lefebvre M.D.,
  Chief Medical Officer
• Dr. Éric Lefebvre M.D.,
  Chief Medical Officer
• Johannes P. Hull,
  Chief Bus. Officer
• Christopher S. Keenan,
  VP of Investor Relations & Corp. Communications
• Craig D. Muir,
  Interim Chief Technology Officer
• Dr. Keith Lamont Cummings M.B.A., M.D.,
  Chief Financial Officer
• Hal Chapman M.D.,
  Scientific Founder & Member of Scientific Advisory Board
• Bill DeGrado Ph.D.,
  Scientific Founder & Member of Scientific Advisory Board
• Dean Sheppard M.D.,
  Scientific Founder & Member of Scientific Advisory Board
• Dr. Rik Derynck,
  Scientific Founder & Member of Scientific Advisory Board
• Katharine Knobil,
  Director
• Rock Ventures Iii, L.P.Thir...,
  
• Hans Hull,
  Chief Business Officer
• Steve E. Krognes,
  Director
• Darren S Cline,
  Director
• Thomas A Mccourt,
  Director
• Group, Llc Green Jeremy Red...,
  
• Hoyoung Huh,
  Director
• Neil Exter,
  Director
• Barbara Howes,
  Chief Human Resource Officer
• Rock Ventures Iii, L.P.Thir...,
  
• David E I Pyott,
  Director
• Gayle A Crowell,
  Director
• John T Curnutte,
  Director
• Charles J Homcy,
  Director
• Suzanne Louise Bruhn,
  Director
• Smital Shah,
  Director
• Bernard Coulie,
  President and CEO
• Mike Ouimette,
  General Counsel & Corp. Sec'y
• Keith Lamont Cummings,
  Chief Financial Officer
• Eric Lefebvre,
  Chief Medical Officer
• Lily Cheung,
  Chief Human Resource Officer